Clinical trial results:
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis

Summary

EudraCT number	2018-001544-64
Trial protocol	DE GB ES HU
Global end of trial date	24 July 2020

Results information

Result version number	v1 (current)
This version publication date	05 August 2021
First version publication date	05 August 2021

Trial information

Trial identification

Sponsor protocol code	R3500-AD-1805

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03738423
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Regeneron Pharmaceuticals, Inc.
Sponsor organisation address	777 Old Saw Mill River Rd., Tarrytown, NY, United States, 10591
Public contact	Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 844-734-6643, clinicaltrials@regeneron.com
Scientific contact	Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 844-734-6643, clinicaltrials@regeneron.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 July 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	24 July 2020
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study was to assess the efficacy of REGN3500 monotherapy in atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult subjects with moderate-to-severe AD.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Spain: 4
Country: Number of subjects enrolled	Czechia: 18
Country: Number of subjects enrolled	Germany: 7
Country: Number of subjects enrolled	Hungary: 8
Country: Number of subjects enrolled	Australia: 9
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Japan: 6
Country: Number of subjects enrolled	Korea, Republic of: 25
Country: Number of subjects enrolled	United States: 48
Worldwide total number of subjects	129
EEA total number of subjects	40

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	122
From 65 to 84 years	7
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 238 subjects were screened at centers in North America (United States of America and Canada), Europe (Czech Republic, Germany, Hungary, Spain, and Poland), and Asia Pacific (Republic of Korea, Japan, and Australia). Out of which, 129 subjects met eligibility criteria and were randomized in this study.

Pre-assignment

Screening details:

Subjects were randomized in 1:1:1:1:1 ratio to 1 of the 5 treatment groups: Placebo every 2 weeks (Q2W); REGN3500 30 milligrams (mg) every 8 weeks (Q8W); REGN3500 100 mg every 4 weeks (Q4W); REGN3500 300 mg Q4W and REGN3500 300 mg Q2W.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Carer, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo Q2W

Arm description:

Subjects received 3 subcutaneous (SC) injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.

Arm type	Placebo
Investigational medicinal product name	Placebo matched to REGN3500
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of placebo matched to REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Arm title	REGN3500 30 mg Q8W

Arm description:

Subjects received 1 SC injection of REGN3500 (30 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.

Arm type	Experimental
Investigational medicinal product name	Placebo matched to REGN3500
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of placebo matched to REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Investigational medicinal product name	REGN3500
Investigational medicinal product code	REGN3500
Other name	Itepekimab
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Arm title	REGN3500 100 mg Q4W

Arm description:

Subjects received 1 SC injection of REGN3500 (100 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 1 SC injection of REGN3500 (100 mg total dose) in combination with 1 SC injection of placebo matched to REGN3500 at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.

Arm type	Experimental
Investigational medicinal product name	Placebo matched to REGN3500
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of placebo matched to REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Investigational medicinal product name	REGN3500
Investigational medicinal product code	REGN3500
Other name	Itepekimab
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Arm title	REGN3500 300 mg Q4W

Arm description:

Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.

Arm type	Experimental
Investigational medicinal product name	Placebo matched to REGN3500
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of placebo matched to REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Investigational medicinal product name	REGN3500
Investigational medicinal product code	REGN3500
Other name	Itepekimab
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Arm title	REGN3500 300 mg Q2W

Arm description:

Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 2, 4, 6, 10, 12 and 14.

Arm type	Experimental
Investigational medicinal product name	Placebo matched to REGN3500
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of placebo matched to REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Investigational medicinal product name	REGN3500
Investigational medicinal product code	REGN3500
Other name	Itepekimab
Pharmaceutical forms	Powder for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received SC injection of REGN3500 on different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms so that the same site was not injected for 2 consecutive administrations.

Number of subjects in period 1	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W
Started	25	26	27
Treated	25	26	26
Completed	11	13	14
Not completed	14	13	13
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	9	12	9
Physician decision	-	-	1
Lost to follow-up	1	-	1
Randomized but never treated	-	-	1
Lack of efficacy	3	1	1
Protocol deviation	1	-	-

Number of subjects in period 1	REGN3500 300 mg Q4W	REGN3500 300 mg Q2W
Started	25	26

Treated	24	26
Completed	10	11
Not completed	15	15
Adverse event, serious fatal	-	1
Consent withdrawn by subject	12	10
Physician decision	-	1
Lost to follow-up	1	-
Randomized but never treated	1	-
Lack of efficacy	1	2
Protocol deviation	-	1

Baseline characteristics

Reporting groups	
Reporting group title	Placebo Q2W
Reporting group description:	
Subjects received 3 subcutaneous (SC) injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.	
Reporting group title	REGN3500 30 mg Q8W
Reporting group description:	
Subjects received 1 SC injection of REGN3500 (30 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.	
Reporting group title	REGN3500 100 mg Q4W
Reporting group description:	
Subjects received 1 SC injection of REGN3500 (100 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 1 SC injection of REGN3500 (100 mg total dose) in combination with 1 SC injection of placebo matched to REGN3500 at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.	
Reporting group title	REGN3500 300 mg Q4W
Reporting group description:	
Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.	
Reporting group title	REGN3500 300 mg Q2W
Reporting group description:	
Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 2, 4, 6, 10, 12 and 14.	

Reporting group values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W
Number of subjects	25	26	27
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	36.6	36.0	37.0
standard deviation	± 14.22	± 16.41	± 14.48
Gender categorical			
Units: Subjects			
Female	14	13	12
Male	11	13	15
Eczema Area and Severity Index (EASI) Score			
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The Full Analysis Set (FAS) includes all randomized subjects and was based on the treatment allocated (as randomized). Here, N = 24 for "REGN3500 300 mg Q4W" arm.			
Units: Score on a Scale			
arithmetic mean	30.3	29.8	33.6
standard deviation	± 11.88	± 12.00	± 11.01

Reporting group values	REGN3500 300 mg Q4W	REGN3500 300 mg Q2W	Total
Number of subjects	25	26	129
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	35.6	38.8	
standard deviation	± 12.56	± 15.44	-
Gender categorical			
Units: Subjects			
Female	14	15	68
Male	11	11	61
Eczema Area and Severity Index (EASI) Score			
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The Full Analysis Set (FAS) includes all randomized subjects and was based on the treatment allocated (as randomized). Here, N = 24 for "REGN3500 300 mg Q4W" arm.			
Units: Score on a Scale			
arithmetic mean	27.7	32.7	
standard deviation	± 10.68	± 15.13	-

End points

End points reporting groups

Reporting group title	Placebo Q2W
Reporting group description:	
Subjects received 3 subcutaneous (SC) injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.	
Reporting group title	REGN3500 30 mg Q8W
Reporting group description:	
Subjects received 1 SC injection of REGN3500 (30 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.	
Reporting group title	REGN3500 100 mg Q4W
Reporting group description:	
Subjects received 1 SC injection of REGN3500 (100 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 1 SC injection of REGN3500 (100 mg total dose) in combination with 1 SC injection of placebo matched to REGN3500 at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.	
Reporting group title	REGN3500 300 mg Q4W
Reporting group description:	
Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.	
Reporting group title	REGN3500 300 mg Q2W
Reporting group description:	
Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 2, 4, 6, 10, 12 and 14.	

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16[1]
End point description:	
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and subjects with missing EASI score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.	
End point type	Primary
End point timeframe:	
Week 16	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Due to the premature discontinuation of the study, all statistical analyses were changed from hypothesis testing to descriptive.

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	7	7
Units: Percentage of Change				
arithmetic mean (standard deviation)	-33.5 (± 41.81)	-57.9 (± 31.65)	-52.7 (± 46.64)	-80.0 (± 10.54)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of Change				
arithmetic mean (standard deviation)	-54.0 (± 36.80)			

Statistical analyses

No statistical analyses for this end point

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16[2]

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percent change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Primary

End point timeframe:

Week 16

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to the premature discontinuation of the study, all statistical analyses were changed from hypothesis testing to descriptive.

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	8	9
Units: Percentage of Change				
arithmetic mean (standard deviation)	-18.9 (± 52.01)	-46.0 (± 45.35)	-48.7 (± 44.66)	-67.0 (± 28.74)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Percentage of Change				
arithmetic mean (standard deviation)	-56.1 (± 35.32)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percentage of Subjects Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of subjects who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 were reported. Values after first rescue treatment were set to missing and subjects with missing EASI score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	7	7
Units: Percentage of Subjects				
number (not applicable)	30.0	71.4	71.4	100

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of Subjects				

number (not applicable)	55.6			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percentage of Subjects Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of subjects who achieved EASI-50 (≥50% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	8	9
Units: Percentage of Subjects				
number (not applicable)	25.0	60.0	62.5	77.8

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Percentage of Subjects				
number (not applicable)	60.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percentage of Subjects Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of subjects who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and subjects with missing EASI score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	7	7
Units: Percentage of Subjects				
number (not applicable)	20.0	28.6	28.6	71.4

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of Subjects				
number (not applicable)	44.4			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percentage of Subjects Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of subjects who achieved EASI-75 (≥75% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	8	9
Units: Percentage of Subjects				
number (not applicable)	16.7	30.0	25.0	55.6

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Percentage of Subjects				
number (not applicable)	40.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percentage of Subjects Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of subjects who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and subjects with missing EASI score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	7	7
Units: Percentage of Subjects				
number (not applicable)	10.0	14.3	28.6	28.6

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of Subjects				
number (not applicable)	33.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percentage of Subjects Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Percentage of subjects who achieved EASI-90 (≥90% Improvement from baseline) at Week 16 based on all observed values regardless of rescue treatment were reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	8	9
Units: Percentage of Subjects				
number (not applicable)	8.3	20.0	25.0	22.2

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Percentage of Subjects				
number (not applicable)	30.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and subjects with missing EASI score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	7	7
Units: Score on a Scale				
arithmetic mean (standard deviation)	-7.80 (± 10.225)	-14.64 (± 8.489)	-14.81 (± 12.614)	-18.19 (± 6.298)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Score on a Scale				
arithmetic mean (standard deviation)	-13.79 (± 9.534)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

The EASI score was used to measure the severity and extent of AD and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Absolute change from baseline in EASI score at Week 16 based on all observed values regardless of rescue treatment was reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	8	9
Units: Score on a Scale				
arithmetic mean (standard deviation)	-4.10 (± 13.079)	-12.07 (± 11.764)	-13.83 (± 12.000)	-15.15 (± 8.299)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Score on a Scale				
arithmetic mean (standard deviation)	-14.68 (± 9.410)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percentage of Subjects With Both Investigator Global Assessment (IGA) Score 0 or 1 (on 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Percentage of subjects with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and subjects with missing IGA score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	7	7	7
Units: Percentage of Subjects				
number (not applicable)	10.0	0.0	28.6	42.9

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of Subjects				
number (not applicable)	33.3			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percentage of Subjects With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at

	Week 16

End point description:

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Percentage of subjects with both IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 based on all observed values regardless of rescue treatment were reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	12	10	8	9
Units: Percentage of Subjects				
number (not applicable)	8.3	0.0	25.0	33.3

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: Percentage of Subjects				
number (not applicable)	30.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

Pruritus NRS was an assessment tool used to report the intensity of a subject's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Subjects were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and subjects with missing IGA score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	7	7	7
Units: Score on a Scale				
arithmetic mean (standard deviation)	-0.53 (± 1.583)	-2.95 (± 3.791)	-4.22 (± 2.372)	-3.34 (± 2.628)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Score on a Scale				
arithmetic mean (standard deviation)	-3.12 (± 3.896)			

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

Pruritus NRS was an assessment tool used to report the intensity of a subject's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Subjects were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Absolute change from baseline in weekly average of daily Peak Pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, “Number of Subjects Analysed” signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	10	8	9
Units: Score on a Scale				
arithmetic mean (standard deviation)	-0.51 (± 1.430)	-2.56 (± 3.563)	-4.19 (± 2.198)	-2.69 (± 2.799)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Score on a Scale				
arithmetic mean (standard deviation)	-3.12 (± 3.896)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in in Weekly Average of Daily Peak NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percent Change From Baseline in in Weekly Average of Daily Peak NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

Pruritus NRS was an assessment tool used to report the intensity of a subject's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Subjects were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on observed values set to missing after rescue treatment was reported. Values after first rescue treatment were set to missing and subjects with missing NRS score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analyzed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	7	7	7
Units: Percent Change				
arithmetic mean (standard deviation)	-6.1 (± 20.65)	-31.6 (± 39.01)	-53.1 (± 29.65)	-43.1 (± 36.42)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percent Change				
arithmetic mean (standard deviation)	-32.2 (± 47.46)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in in Weekly Average of Daily Peak NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percent Change From Baseline in in Weekly Average of Daily Peak NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

Pruritus NRS was an assessment tool used to report the intensity of a subject's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Subjects were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percent change from baseline in weekly average of daily peak pruritus NRS score at Week 16 based on all observed values regardless of rescue treatment was reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	10	8	9
Units: Percent Change				
arithmetic mean (standard deviation)	-5.9 (± 18.62)	-27.5 (± 39.24)	-52.8 (± 27.47)	-33.9 (± 38.71)

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percent Change				
arithmetic mean (standard deviation)	-32.2 (± 47.46)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Improvement in Weekly Average of Peak Daily Pruritus NRS Score ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point title	Percentage of Subjects With Improvement in Weekly Average of Peak Daily Pruritus NRS Score ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16

End point description:

Pruritus NRS was an assessment tool used to report the intensity of a subject's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Subjects were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percentage of subjects with improvement of weekly average of daily peak pruritus NRS score ≥4 from baseline to Week 16 based on observed values set to missing after rescue treatment were reported. Values after first rescue treatment were set to missing and subjects with missing NRS score at Week 16 were counted as non-responders. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	7	7	7
Units: Percentage of Subjects				
number (not applicable)	0.0	42.9	57.1	28.6

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percentage of Subjects				
number (not applicable)	50.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Improvement in Weekly Average of Daily Peak Pruritus NRS Score ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point title	Percentage of Subjects With Improvement in Weekly Average of Daily Peak Pruritus NRS Score ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16

End point description:

Pruritus NRS was an assessment tool used to report the intensity of a subject's pruritus (itch), both maximum and average intensity, using an electronic questionnaire (e-diary). Subjects were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 [0 = no itch; 10 = worst itch imaginable]). Percentage of subjects with improvement of weekly average of daily peak pruritus NRS score ≥4 from baseline to Week 16 based on all observed values regardless of rescue treatment were reported. FAS included all randomized subjects and was based on the treatment allocated (as randomized). Here, "Number of Subjects Analysed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	10	8	9
Units: Percentage of Subjects				
number (not applicable)	0.0	40.0	62.5	22.2

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percentage of Subjects				
number (not applicable)	50.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Onset of Effect on Pruritus (≥4-point reduction of weekly average of daily peak Pruritus NRS from baseline)

End point title	Time to Onset of Effect on Pruritus (≥4-point reduction of weekly average of daily peak Pruritus NRS from baseline)

End point description:

Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) during a 24-hour recall period. Subjects were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?"

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25[3]	26[4]	27[5]	25[6]
Units: Hours				
median (full range (min-max))	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

Notes:

[3] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[4] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[5] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[6] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26[7]			
Units: Hours				
median (full range (min-max))	99999 (99999 to 99999)			

Notes:

[7] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

Statistical analyses

No statistical analyses for this end point

Secondary: Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

End point title	Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16

End point description:

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25[8]	26[9]	27[10]	25[11]
Units: Percent of change				
arithmetic mean (standard deviation)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)

Notes:

[8] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[9] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[10] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[11] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26[12]			
Units: Percent of change				
arithmetic mean (standard deviation)	99999 (± 99999)			

Notes:

[12] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16

End point title	Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16

End point description:

End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25[13]	26[14]	27[15]	25[16]
Units: Score on a Scale				
arithmetic mean (standard deviation)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)	99999 (± 99999)

Notes:

[13] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[14] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

[15] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized
[16] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26[17]			
Units: Score on a Scale				
arithmetic mean (standard deviation)	99999 (± 99999)			

Notes:

[17] - Due to premature discontinuation, all analyses were changed to descriptive and were not summarized

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 16

End point title	Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 16

End point description:

AE: any untoward medical occurrence in a subject administered a study drug which may/may not have a causal relationship with study drug. Serious AE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-subject hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE was defined as AEs starting/worsening after first intake of the study drug. TEAEs included serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic reactions; Systemic/severe hypersensitivity reactions; Malignancy; Helminthic infections; Suicide-related events; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; Conjunctivitis and significant ALT elevation. Safety analysis set (SAF) included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 16

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects				
Subjects with TEAEs	9	13	12	9
Subjects with Serious TEAEs	0	0	0	0
Subjects with AESIs	0	0	1	0

End point values	REGN3500 300 mg Q2W			

Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects				
Subjects with TEAEs	15			
Subjects with Serious TEAEs	2			
Subjects with AESIs	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 36

End point title	Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) up to Week 36

End point description:

AE: any untoward medical occurrence in a subject administered a study drug which may/may not have a causal relationship with study drug. Serious AE: any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-subject hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAE was defined as AEs starting/worsening after first intake of the study drug. TEAEs included serious TEAEs and Non-serious TEAEs. AESI included: Anaphylactic reactions; Systemic/severe hypersensitivity reactions; Malignancy; Helminthic infections; Suicide-related events; Severe injection site reactions; Mycosis fungoides/other forms of cutaneous T-cell lymphoma; Conjunctivitis and significant ALT elevation. SAF included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects				
Subjects with TEAEs	11	14	14	13
Subjects with Serious TEAEs	0	0	0	1
Subjects with AESIs	0	0	1	0

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects				
Subjects with TEAEs	15			
Subjects with Serious TEAEs	2			
Subjects with AESIs	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Changes From Baseline in Laboratory Parameters

End point title	Number of Subjects With Clinically Significant Changes From Baseline in Laboratory Parameters

End point description:

The laboratory measurements included hematology, blood chemistry, urinalysis and pregnancy testing. Number of subjects with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was decided by investigator. SAF included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects	0	0	0	0

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Changes From Baseline in Vital Signs

End point title	Number of Subjects With Clinically Significant Changes From Baseline in Vital Signs

End point description:

Vital sign assessment included blood pressure, heart rate, body temperature and respiration rate. Number of subjects with clinically significant changes form baseline in vital signs were reported. Clinical

significance was decided by Investigator. SAF included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects	0	0	0	0

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Changes From Baseline in 12-lead Electrocardiogram (ECG)

End point title	Number of Subjects With Clinically Significant Changes From Baseline in 12-lead Electrocardiogram (ECG)

End point description:

The ECG recordings included ventricular heart rate, PR interval, QRS interval and corrected QT interval. Number of subjects with clinically significant changes from baseline in ECG were reported. Clinical significance was decided by Investigator. SAF included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects	0	0	0	0

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Ophthalmological Symptoms Reported as TEAEs

End point title	Number of Subjects With Ophthalmological Symptoms Reported as TEAEs

End point description:

Number of subjects with ophthalmological symptoms (conjunctivitis, blepharitis, or keratitis) assessed as TEAEs were reported. SAF included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects				
Conjunctivitis	0	1	0	1
Conjunctivitis allergic	0	0	0	1

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects				
Conjunctivitis	0			
Conjunctivitis allergic	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Clinically Significant Changes From Baseline in

Physical Examination Findings

End point title	Number of Subjects With Clinically Significant Changes From Baseline in Physical Examination Findings

End point description:

Number of subjects with clinically significant changes from baseline in physical examination findings were reported. Clinical significance was decided by Investigator. SAF included all randomized subjects who received any study drug and was based on the treatment received (as treated).

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	26	26	24
Units: Subjects	0	0	0	0

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Subjects	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Functional REGN3500

End point title	Serum Concentration of Functional REGN3500[18]

End point description:

Serum Concentration of Functional REGN3500 was reported. The Pharmacokinetic (PK) analysis set included all randomized subjects who received any study drug and who had at least 1 non-missing study drug concentration result following the first dose of study drug. Here, "n" signifies those subjects who were evaluable at given time points.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32 and 36

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The Pharmacokinetic (PK) analysis set only included all randomized subjects who received any study drug and who had at least 1 non-missing study drug concentration result following the first dose of study drug.

End point values	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W	REGN3500 300 mg Q2W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	26	24	26
Units: Milligrams per Liter (mg/L)				
arithmetic mean (standard deviation)				
Week 0: (n = 26, 26, 24, 26)	0 (± 0)	0.157 (± 0.800)	0 (± 0)	0 (± 0)
Week 2: (n = 25, 25, 22, 25)	3.29 (± 2.70)	7.35 (± 5.65)	21.4 (± 9.83)	22.0 (± 11.0)
Week 4: (n = 22, 21, 23, 21)	2.33 (± 1.82)	5.14 (± 3.73)	14.3 (± 7.05)	37.9 (± 15.2)
Week 8: (n = 19, 20, 22, 15)	1.41 (± 1.99)	9.27 (± 5.33)	23.3 (± 10.4)	51.4 (± 20.7)
Week 12: (n = 14, 14, 17, 13)	2.63 (± 2.20)	8.74 (± 6.37)	30.3 (± 12.0)	57.7 (± 26.3)
Week 16: (n = 11, 11, 12, 13)	1.05 (± 0.733)	10.6 (± 4.91)	35.2 (± 17.3)	60.8 (± 33.3)
Week 20: (n = 13, 8, 9, 9)	0.523 (± 0.441)	5.03 (± 3.93)	12.4 (± 6.58)	29.8 (± 23.5)
Week 24: (n = 8, 6, 8, 7)	0.170 (± 0.157)	2.23 (± 1.24)	7.14 (± 5.22)	12.1 (± 14.4)
Week 28: (n = 8, 6, 6, 7)	0.0838 (± 0.109)	1.08 (± 0.813)	3.49 (± 2.76)	6.70 (± 7.64)
Week 32: (n = 8, 6, 6, 8)	0.0171 (± 0.0484)	0.625 (± 0.560)	1.93 (± 1.37)	3.73 (± 5.41)
Week 36: (n = 8, 6, 6, 7)	0 (± 0)	0.299 (± 0.250)	0.960 (± 0.741)	1.02 (± 1.31)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Positive Treatment-Emergent Anti-REGN3500 Antibodies (ADA)

End point title	Number of Subjects With Positive Treatment-Emergent Anti-REGN3500 Antibodies (ADA)

End point description:

Treatment-Emergent (TE) ADA was defined as any positive post baseline assay response when baseline results were negative or missing. TE ADA responses were further classified as: - persistent (treatment-emergent positive ADA response detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period [based on nominal sampling time], with no ADA-negative samples in-between, regardless of any missing samples or a positive response at the last ADA sampling time point),- indeterminate (a positive assay response at the last collection time point only, regardless of any missing samples), - transient (not persistent/indeterminate, regardless of any missing samples). The Anti-drug Antibodies (ADA) analysis set included all treated subjects who received any amount of study drug (active or placebo [safety analysis set]) and had at least one non-missing anti-REGN3500 result following the first dose of study drug or placebo.

End point type	Secondary

End point timeframe:

Baseline up to Week 36

End point values	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W	REGN3500 300 mg Q4W
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	25	25	22
Units: Subjects				
TE Persistent	0	0	0	0
TE Transient	0	0	0	0
TE Indeterminate	0	0	0	0

End point values	REGN3500 300 mg Q2W			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Subjects				
TE Persistent	0			
TE Transient	0			
TE Indeterminate	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (Week 36) regardless of seriousness or relationship to investigational product (IP).

Adverse event reporting additional description:

SAF included all randomized participants who received any study drug and was based on the treatment received (as treated).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23

Reporting groups

Reporting group title	Placebo Q2W

Reporting group description:

Subjects received 3 subcutaneous (SC) injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.

Reporting group title	REGN3500 30 mg Q8W

Reporting group description:

Subjects received 1 SC injection of REGN3500 (30 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 4, 6, 10, 12, and 14.

Reporting group title	REGN3500 100 mg Q4W

Reporting group description:

Subjects received 1 SC injection of REGN3500 (100 mg total dose) along with 2 SC injections of placebo matched to REGN3500 on Day 1 and Week 8 and 1 SC injection of REGN3500 (100 mg total dose) in combination with 1 SC injection of placebo matched to REGN3500 at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500
at Weeks 2, 6, 10, and 14.

Reporting group title	REGN3500 300 mg Q4W

Reporting group description:

Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 4 and 12 and 2 SC injections of placebo matched to REGN3500 at Weeks 2, 6, 10, and 14.

Reporting group title	REGN3500 300 mg Q2W

Reporting group description:

Subjects received 2 SC injections of REGN3500 (300 mg total dose) along with 1 SC injection of placebo matched to REGN3500 on Day 1 and Week 8 and 2 SC injections of REGN3500 (300 mg total dose) at Weeks 2, 4, 6, 10, 12 and 14.

Serious adverse events	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 25 (0.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			

subjects affected / exposed	0 / 25 (0.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Road traffic accident			
subjects affected / exposed	0 / 25 (0.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis norovirus			
subjects affected / exposed	0 / 25 (0.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	REGN3500 300 mg Q4W	REGN3500 300 mg Q2W	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 24 (4.17%)	2 / 26 (7.69%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 24 (4.17%)	0 / 26 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Road traffic accident			
subjects affected / exposed	0 / 24 (0.00%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Infections and infestations			
Gastroenteritis norovirus			
subjects affected / exposed	0 / 24 (0.00%)	1 / 26 (3.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo Q2W	REGN3500 30 mg Q8W	REGN3500 100 mg Q4W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 25 (28.00%)	11 / 26 (42.31%)	9 / 26 (34.62%)
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 25 (4.00%)	1 / 26 (3.85%)	0 / 26 (0.00%)
occurrences (all)	1	1	0
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	0 / 25 (0.00%)	2 / 26 (7.69%)	0 / 26 (0.00%)
occurrences (all)	0	2	0
Gastrointestinal disorders			
Toothache			
subjects affected / exposed	1 / 25 (4.00%)	0 / 26 (0.00%)	1 / 26 (3.85%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	1 / 25 (4.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	3 / 25 (12.00%)	8 / 26 (30.77%)	5 / 26 (19.23%)
occurrences (all)	3	9	5
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 25 (0.00%)	2 / 26 (7.69%)	4 / 26 (15.38%)
occurrences (all)	0	2	4
Bronchitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Cellulitis			

subjects affected / exposed	0 / 25 (0.00%)	1 / 26 (3.85%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	2 / 25 (8.00%)	0 / 26 (0.00%)	0 / 26 (0.00%)
occurrences (all)	2	0	0

Non-serious adverse events	REGN3500 300 mg Q4W	REGN3500 300 mg Q2W	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 24 (33.33%)	10 / 26 (38.46%)	
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 24 (0.00%)	2 / 26 (7.69%)	
occurrences (all)	0	2	
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	0 / 24 (0.00%)	1 / 26 (3.85%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Toothache			
subjects affected / exposed	0 / 24 (0.00%)	2 / 26 (7.69%)	
occurrences (all)	0	2	
Nausea			
subjects affected / exposed	2 / 24 (8.33%)	0 / 26 (0.00%)	
occurrences (all)	2	0	
Skin and subcutaneous tissue disorders			
Dermatitis atopic			
subjects affected / exposed	5 / 24 (20.83%)	6 / 26 (23.08%)	
occurrences (all)	5	7	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	2 / 24 (8.33%)	3 / 26 (11.54%)	
occurrences (all)	2	3	
Bronchitis			
subjects affected / exposed	0 / 24 (0.00%)	2 / 26 (7.69%)	
occurrences (all)	0	3	
Cellulitis			

subjects affected / exposed	2 / 24 (8.33%)	1 / 26 (3.85%)	
occurrences (all)	2	1	
Urinary tract infection			
subjects affected / exposed	1 / 24 (4.17%)	0 / 26 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 September 2018	- Modified exclusion criterion #4 to decrease the length of the washout period from 12 weeks to 4 weeks before the baseline visit for immunosuppressive/immunomodulating drugs (eg, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon-gamma [IFN-gamma], Janus kinase inhibitors, azathioprine, methotrexate, etc) and phototherapy. These washout changes were consistent with the prior dupilumab adult atopic dermatitis phase 3 studies (eg, R668-AD-1224) and acceptable for subjects enrolled in this study - Updated exclusion criterion #11 to be consistent with prior dupilumab adult atopic dermatitis phase 3 studies (eg, R668-AD-1224). Active chronic or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks (was previously 8 weeks before the screening visit) before the baseline visit, or superficial skin infections within 1 week (was previously 4 weeks before the screening visit) before the baseline visit
29 November 2018	- Added text in Exclusion Criterion #12 to specify that subjects with a positive tuberculosis (TB) QuantiFERON test result will be excluded from the study - Exclusion Criterion # 20: Added myocardial infarction, unstable arterial hypertension, unstable angina, and cerebrovascular accident as examples of uncontrolled cerebrocardiovascular conditions that will exclude a subject from the study - Exclusion Criterion #25: Added clarification that the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient, based on Clinical Trial Facilitation Group guideline on contraception
03 January 2019	- Added secondary safety and pharmacokinetic (PK) endpoints

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
12 February 2020	The decision was made by the sponsor to terminate the study on 12 Feb 2020 due to lack of efficacy. Study enrollment was not complete at that time, therefore planned sample sizes were not met. Subjects discontinued study drug and transitioned into the post-treatment follow-up period.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As a result of the decision to terminate the study, all statistical analyses were descriptive and no hypothesis testing was performed.

Notes: